Celularity (CELU) Projected to Post Quarterly Earnings on Thursday

Celularity (NASDAQ:CELU) is expected to issue its Q4 2025 resultson Thursday, March 26th. Analysts expect the company to announce earnings of ($1.50) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Celularity Price Performance

CELU stock opened at $1.27 on Wednesday. Celularity has a 12 month low of $1.01 and a 12 month high of $4.35. The firm’s 50-day moving average is $1.27 and its 200 day moving average is $1.62. The company has a market capitalization of $36.63 million, a PE ratio of -0.38 and a beta of 0.79.

Hedge Funds Weigh In On Celularity

A number of institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Celularity in the fourth quarter valued at approximately $33,000. Jane Street Group LLC bought a new stake in Celularity during the 4th quarter valued at $46,000. Geode Capital Management LLC raised its position in Celularity by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after purchasing an additional 20,876 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after buying an additional 176,518 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the period. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.